var data={"title":"Nabiximols (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nabiximols (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/39681?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nabiximols-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nabiximols (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F596136\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sativex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F596139\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Nonopioid;</li>\n      <li>\n        Skeletal Muscle Relaxant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F608937\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Spasticity or neuropathic pain associated with multiple sclerosis (MS), cancer pain:</b> Buccal spray:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Initial: One spray in the morning and one spray in the afternoon or evening (maximum initial dose: 2 sprays on first day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Titration and individualization: Dosage is self-titrated by the patient. After initiation of therapy, the dose may be increased each subsequent day by one spray as needed and tolerated. Usual dosage: 4 to 8 sprays daily. Most patients require &le;12 sprays daily. Experience is limited with dosage of &gt;12 sprays daily, although some patients may require and tolerate higher dosing. Sprays should be evenly distributed over the course of the day during initial titration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990926\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling (has not been studied). Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988214\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling (has not been studied). Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062234\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution and monitor closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10839907\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">If adverse reactions, including intoxication-type symptoms, are noted the dosage should be suspended until resolution of the symptoms; a dosage reduction or extension of the interval between doses may be used to avoid a recurrence of symptoms. Retitration may be required in the event of adverse reactions and/or worsening of symptoms. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5951003\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, buccal [spray]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sativex: Delta-9 tetrahydrocannabinol 27 mg/mL and cannabidiol 25 mg/mL 10 mL [delivers 90 metered sprays]) [100 microliters/spray; contains ethanol 50%, peppermint oil, and propylene glycol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234346\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F596134\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">CDSA-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F608940\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For buccal use only. Do not inhale, spray into nose or towards throat. Do not apply spray to sore or inflamed mucosa.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Shake vial before use and remove protective cap; replace protective cap following use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Priming: Vial should be held in an upright position and primed into a tissue prior to the initial use by depression of the actuator 2 to 3 times until a fine spray appears. Priming should not be required for subsequent uses. Do not spray near children, pets, or an open flame.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Normal use: Hold vial in upright position and spray into mouth; spray should be directed at varied sites below the tongue or on the inside of the cheeks, avoiding direction to the pharynx. Initiate therapy by administering 1 spray in the morning (between waking up and 12 noon) and 1 spray in the afternoon or evening (between 4 pm and bedtime) on day 1. With subsequent titration, allow at least 15 minutes between sprays; however, during initial titration, sprays should be evenly spaced throughout the day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F596140\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis: </b>Adjunctive treatment in adults with multiple sclerosis for the symptomatic relief of neuropathic pain and of spasticity that is nonresponsive to other therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain: </b>Adjunctive analgesic treatment in adults with advanced cancer with moderate-to-severe pain at the highest tolerated dose of strong opioid therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26116841\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F608889\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Central nervous system: Dizziness (12% to 25%), drowsiness (8% to 15%), fatigue (13%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Gastrointestinal: Nausea (10% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Cardiovascular: Hypotension (5%), palpitations (1%), syncope (1%), tachycardia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Central nervous system: Confusion (7%), vertigo (5% to 7%), disorientation (4%), disturbance in attention (3% to 4%), depression (3%), equilibrium disturbance (3%), headache (3%), insomnia (3%), intoxicated feeling (3%), panic attack (3%), euphoria (2% to 3%), hallucination (&le;3%), depersonalization (2%), dysarthria (2%), falling (2%), feeling abnormal (2%), lethargy (2%), amnesia (1%), malaise (1%), memory impairment (1%), paranoia (1%), suicidal ideation (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Gastrointestinal: Vomiting (4% to 8%), diarrhea (6% to 7%), xerostomia (6%), dysgeusia (3%), glossalgia (3%), oral candidiasis (3%), anorexia (2%), constipation (2%), dental discoloration (2%), oral mucosa changes (2%), oral mucosa ulcer (2%), abdominal pain (1%), increased appetite (1%), stomatitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Genitourinary: Urinary retention (5%), hematuria (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Hepatic: Abnormal hepatic function tests (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (5% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Ophthalmic: Blurred vision (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Respiratory: Throat irritation (1%) </p>\n    <p style=\"text-indent:0em;\">&lt;1%, postmarketing, frequency not defined, and/or case reports: Delusions, hypertension, illusion, oral leukoplakia, urinary tract infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F608885\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cannabinoids, propylene glycol, ethanol, peppermint oil, or any other component of the formulation; serious cardiovascular disease (including arrhythmias, severe heart failure, poorly controlled hypertension, and ischemic heart disease); history of schizophrenia or any other psychotic disorder; women of childbearing potential who are not using a reliable form of contraception; males intending to start a family; pregnancy; breast-feeding; children &lt;18 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F608886\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Buccal mucosa irritation: May be irritating to the buccal mucosa; avoid administration in an area of soreness or inflammation. Inspect oral mucosa regularly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: <b>[Canadian Boxed Warning]: May be associated with adverse cardiovascular effects, including tachycardia and transient alterations in blood pressure (including orthostatic changes).</b> Dosage must be carefully titrated and monitored, with downward adjustment in patients with unacceptable adverse events. Use with caution in the perioperative setting. Use is contraindicated in ischemic heart disease, arrhythmias, poorly-controlled hypertension, and severe heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: <b>[Canadian Boxed Warning]: Use may be associated with dizziness, changes in mood, cognitive performance, or memory, impulsivity, and coordination, as well as an altered perception of reality, particularly with respect to an awareness/sensation of time.</b> Adverse effects are dose-related and vary among patients. Dose reductions, greater intervals between doses, or interrupting therapy may resolve unwanted effects. Interrupt therapy if patient is confused or disoriented. May impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Genitourinary effects: Increased risk for urinary retention and infection, especially in cancer patients; use caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Substance abuse: <b>[Canadian Boxed Warning]: Potential for dependency exists. Tolerance, psychological, and physical dependence may occur with prolonged use.</b> Use with caution in patients with a history of drug or alcohol abuse.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic dysfunction: Use in patients with significant hepatic dysfunction has not been studied. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Avoid use in patients with personal or strong familial history of psychosis; symptoms may be aggravated with cannabinoids. Suicidal ideation and other symptoms associated with depression have been reported. Discontinue use immediately in patients experiencing psychotic reactions, suicidal ideation, delusions, hallucinations, disorientation, and/or confusion and monitor until complete resolution of symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal dysfunction: Use in patients with significant renal dysfunction has not been studied. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: <b>[Canadian Boxed Warning]: Use with caution in patients with a history of seizure disorder.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol/CNS depressants: <b>[Canadian Boxed Warning]: Concomitant use with ethanol or drugs with sedative, hypnotic or psychotropic effects may have potentiate adverse CNS effects; use caution.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly. Close monitoring is required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol: Formulation contains ethanol; use with caution in alcoholism and/or hepatic dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prescribing restrictions: <b>[Canadian Boxed Warning]: Prescriptions should be written for the minimal amount needed between clinic visits.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Toxicology screen: Cannabinoids accumulate in body fat and may be detectable in the urine and serum for several weeks following drug discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F608924\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F608923\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9457&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Tetrahydrocannabinol may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the tachycardic effect of Cannabinoid-Containing Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloBAZam: Cannabidiol may increase serum concentrations of the active metabolite(s) of CloBAZam. Cannabidiol may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: Tetrahydrocannabinol may enhance the CNS depressant effect of CNS Depressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the tachycardic effect of Cannabinoid-Containing Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Tetrahydrocannabinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May increase the serum concentration of Tetrahydrocannabinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Tetrahydrocannabinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Tetrahydrocannabinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tetrahydrocannabinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F608882\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated during pregnancy, in women of childbearing potential not using reliable contraception, and in males intending to start a family.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Cannabinoids have been associated with reproductive toxicity. Animal studies indicate possible effects on fetal development and spermatogenesis. Women of childbearing potential and males who are capable of causing pregnancy should use a reliable form of contraception for the duration of treatment and for 3 months following discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49062705\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in women who are breast-feeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F608944\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Mental status, response to pain; mucosal integrity and inflammation; signs/symptoms of psychosis and/or suicidal ideation; signs/symptoms of misuse/abuse</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F608941\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates cannabinoid receptors CB1 and CB2 in the CNS and dorsal root ganglia as well as other sites in the body. Cannabinoid receptors in the pain pathways of the brain and spinal cord mediate cannabinoid-induced analgesia. Peripheral CB2 receptors modulate immune function through cytokine release.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F608954\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapidly absorbed (within 30 minutes) from the buccal mucosa</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Widely distributed, particularly to fatty tissues</p>\n    <p style=\"text-indent:0em;\">Protein binding: Extensive</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, via CYP isoenzymes (2C9, 2C19, 2D6 and 3A4) to THC metabolite 11-hydroxy-tetrahydrocannabinol (11-OH-THC, psycho-active) and CBD metabolite 7-hydroxy-cannabidiol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Biphasic: Initial: 1 to 2 hours; Terminal: 24 to 36 hours (or longer) secondary to redistribution from fatty tissue</p>\n    <p style=\"text-indent:0em;\">Time to peak, plasma: 2 to 4 hours</p>\n    <p style=\"text-indent:0em;\">Excretion: As metabolites, urine and feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869443\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Sativex (AT, AU, CZ, DE, DK, ES, FI, FR, GB, IS, NL, NO, NZ, PL, PT, SE, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Berman JS, Symonds C, and Birch R, &quot;Efficacy of Two Cannabis Based Medicinal Extracts for Relief of Central Neuropathic Pain From Brachial Plexus Avulsion: Results of a Randomised Controlled Trial,&quot; <i>Pain</i>, 2004, 112(3):299-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nabiximols-united-states-not-available-drug-information/abstract-text/15561385/pubmed\" target=\"_blank\" id=\"15561385\">15561385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Djulus J, Moretti M, and Koren G, &quot;Marijuana Use and Breastfeeding,&quot; <i>Can Fam Physician</i>, 2005, 51:349-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nabiximols-united-states-not-available-drug-information/abstract-text/15794018/pubmed\" target=\"_blank\" id=\"15794018\">15794018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kozer E and Koren G, &quot;Effects of Prenatal Exposure to Marijuana,&quot; <i>Can Fam Physician</i>, 2001, 47:263-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nabiximols-united-states-not-available-drug-information/abstract-text/11228023/pubmed\" target=\"_blank\" id=\"11228023\">11228023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sativex (tetrahydrocannabinol and cannabidiol) [Canadian product monograph]. Histon, Cambridge, United Kingdom: GW Pharma Ltd; March 2015<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nabiximols-united-states-not-available-drug-information/abstract-text/15298072/pubmed\" target=\"_blank\" id=\"15298072\">15298072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wade DT, Makela P, Robson P, et al, &quot;Do Cannabis-Cased Medicinal Extracts Have General or Specific Effects on Symptoms in Multiple Sclerosis? A Double-Blind, Randomized, Placebo-Controlled Study on 160 Patients,&quot; <i>Mult Scler</i>, 2004, 10(4):434-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nabiximols-united-states-not-available-drug-information/abstract-text/15327042/pubmed\" target=\"_blank\" id=\"15327042\">15327042</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9457 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F596136\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F596139\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F608937\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990926\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988214\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062234\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F10839907\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5951003\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11234346\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F596134\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F608940\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F596140\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F26116841\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F608889\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F608885\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F608886\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F608924\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F608923\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F608882\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F49062705\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F608944\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F608941\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F608954\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869443\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9457|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nabiximols-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Nabiximols (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}